
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics is a promising biopharmaceutical company with a solid pipeline of potential treatments for orphan pulmonary and fibrosis indications. The recent updates and financing have significantly reduced the company's risk and granted it a clearer path towards the Phase 2 readout of its lead candidate, LTI-03. With its unique mechanism of action targeting both fibrotic signaling and epithelial repair, LTI-03 has the potential to be a differentiated IPF asset, with a favorable risk-reward from current levels. However, risks to the company's forecasts and thesis include financing, development, and regulatory risks.
Bears say
Rein Therapeutics is quickly moving towards the end of its Phase 2 trial for its lead candidate LTI-03, but with no approved treatments for the targeted indications, there is a high risk that the trial will not show meaningful clinical benefit. Additionally, while the recent financing may provide enough funding for the trial to be completed, the dilution caused by the oversubscribed offering could potentially limit future upside for the stock. Overall, the company's high reliance on LTI-03 and lack of a diversified pipeline make it a risky investment option.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares